ANI Pharmaceuticals (FRA:BSFA) Cyclically Adjusted FCF per Share: €0.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BSFA ANI Pharmaceuticals Inc FRA:BSFA
78 GF Score
Price €66.00
GF Value €85.45
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ANI Pharmaceuticals Cyclically Adjusted FCF per Share?

ANI Pharmaceuticals FRA:BSFA -2.94% 78 Cyclically Adjusted FCF per Share is €0.16 as of Mar. 2026. GuruFocus rates FRA:BSFA with a GF Score™ of 78/100 and a GF Value™ of €85.45 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ANI Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was €1.889. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.16 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 27.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 24.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 22.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ANI Pharmaceuticals was 31.60% per year. The lowest was 0.50% per year. And the median was 14.60% per year.

As of today (2026-08-08), ANI Pharmaceuticals's current stock price is €66.00. ANI Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €0.16. ANI Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 412.50.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ANI Pharmaceuticals was 452.79. The lowest was 390.58. And the median was 418.37.


ANI Pharmaceuticals  (FRA:BSFA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

ANI Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=66.00/0.16
=412.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ANI Pharmaceuticals was 452.79. The lowest was 390.58. And the median was 418.37.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ANI Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


ANI Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ANI Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANI Pharmaceuticals Cyclically Adjusted FCF per Share Chart

ANI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.64 -2.36 -1.95 -1.68 -0.80

ANI Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.58 -1.17 -0.86 -0.80 0.16

FRA:BSFA vs TRLV, AMLX, XERS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


FRA:BSFA
78GF Score
ANI Pharmaceuticals Inc FRA:BSFA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ANI Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ANI Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.889/330.2130*330.2130
=1.889

Current CPI (Mar. 2026) = 330.2130.

ANI Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -4.449 241.018 -6.095
201609 0.000 241.428 0.000
201612 0.871 241.432 1.191
201703 -3.736 243.801 -5.060
201706 -0.176 244.955 -0.237
201709 1.049 246.819 1.403
201712 -2.508 246.524 -3.359
201803 1.431 249.554 1.894
201806 0.170 251.989 0.223
201809 0.504 252.439 0.659
201812 1.956 251.233 2.571
201903 -0.449 254.202 -0.583
201906 0.057 256.143 0.073
201909 1.492 256.759 1.919
201912 0.258 256.974 0.332
202003 -4.246 258.115 -5.432
202006 1.338 257.797 1.714
202009 -0.525 260.280 -0.666
202012 -0.536 260.474 -0.680
202103 1.393 264.877 1.737
202106 -1.491 271.696 -1.812
202109 -0.420 274.310 -0.506
202112 -0.783 278.802 -0.927
202203 -1.188 287.504 -1.364
202206 -0.744 296.311 -0.829
202209 -0.384 296.808 -0.427
202212 -0.436 296.797 -0.485
202303 1.077 301.836 1.178
202306 0.713 305.109 0.772
202309 1.353 307.789 1.452
202312 1.898 306.746 2.043
202403 0.648 312.332 0.685
202406 0.623 314.175 0.655
202409 0.326 315.301 0.341
202412 0.657 315.605 0.687
202503 0.699 319.799 0.722
202506 2.942 322.561 3.012
202509 1.531 324.800 1.557
202512 1.115 324.054 1.136
202603 1.889 330.213 1.889

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.16 mean?
ANI Pharmaceuticals (FRA:BSFA) has a Cyclically Adjusted FCF per Share of €0.16 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ANI Pharmaceuticals and its competitors.
Is ANI Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
ANI Pharmaceuticals' current Cyclically Adjusted FCF per Share is €0.16. Overall, ANI Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Cyclically Adjusted FCF per Share compare to TRLV and AMLX?
ANI Pharmaceuticals' Cyclically Adjusted FCF per Share of €0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ANI Pharmaceuticals and its competitors. ANI Pharmaceuticals's current Cyclically Adjusted FCF per Share is €0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (FRA:BSFA) is currently considered Modestly Undervalued. The stock's GF Value™ is €85.45, compared to a current price of €66.00 — trading 22.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.16. ANI Pharmaceuticals' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ANI Pharmaceuticals (FRA:BSFA), the current Cyclically Adjusted FCF per Share is €0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ANI Pharmaceuticals (FRA:BSFA) Overvalued in 2026?

Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued. The current stock price of €66.00 is trading 22.8% below its estimated GF Value™ of €85.45. GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for FRA:BSFA:

  • Cyclically Adjusted FCF per Share: €0.16
  • GF Value™: €85.45 vs. price of €66.00 (22.8% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the FRA:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ANI Pharmaceuticals Business Description

Other Exchanges ANIP:USA
Address 210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
78GF Score

Get the complete analysis for FRA:BSFA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.00
Price
€85.45
GF Value